success stories

Agilux Laboratories

Acquired by Charles River Laboratories

Alpha-Beta Technology, Inc.

Acquisition

Alpha-Beta was the second ever startup company to enter the MBI incubator. The company reached a peak headcount of 220 employees and peak market capitalization of $350 million, before being sold in 1999. Products developed by the startup are now marketed as Wellmune by Kerry, a global health and nutrition company.

Antigen Express, Inc

Acquired by Generex

Avatar Pharmaceuticals

Acquired by Vertex Pharmaceuticals

Averica Discovery Services Inc

Acquired by NeoPharm

Beckman Coulter

Acquired by Danaher

Biocytogen, LLC

IPO, $335M+

Bioflash Partners, LLC

Acquired by Repligen

Biomere

Acquired by JOINN Laboratories Co. Ltd.

Blue Sky Biotech, Inc

Acquired by Curia

Coley Pharmaceutical Group, Inc

Acquired by Pfizer

Convergent Dental

$115M+ raised, commercialized product

Convergent Dental, Inc. is a privately owned dental equipment and technology company. The Company’s flagship product, Solea®, is the only CO2 laser to be cleared by the FDA for all-tissue indications and delivers an anesthesia-free, blood-free, suture-free experience that dentists can rely on.

Creoptix

Acquired by Malvern Panalytical

DXA Resource Group, Inc.

Founded in 2002, DRG recognized the need for cost-effective and responsive DXA (Dual- Emission X-Ray Absorptiometry) clinical quality assurance, project management and data management services to support drug development.

ECI Biotech

Acquired by Alira Health

Eden Research

GQ Life Sciences

Acquired by Aptean

HSRL, Inc.

Acquired by StageBio

HSRL started their Massachusetts presence at MBI in 2016 and grew their sales to the point where they secured an investment from Ampersand Capital, acquired a few companies and rebranded as StageBio. StageBio is a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving services for the biopharmaceutical, medical device, academic, and contract research industries.

Intelligent Bio-Systems

Acquired by Qiagen

Invetx

IPO, $80M+

iVexSol

Series A

iVexSol, whose mission is to improve patients' lives by developing transformative vector production technologies, graduated from MBI in 2022 with 20+ employees and has raised $40M to date.

Nyla Laboratories

Acquired

Phio Pharmaceuticals

IPO

Phio's focus is centered on the application of self-delivering RNAi therapies in the field of immuno-oncology. Our INTASYL technology is the only self-delivering siRNA technology focused on immuno-oncology. INTASYL is designed to silence specific genes that are implicated in the proliferation of solid cancer tumors.

Spring Bank Pharmaceuticals

Acquired by F-Star Therapeutics, Inc.

T2 Biosystems

IPO

Targeted Pharmaceuticals

Acquired by Tetra Bio-Pharma

Tarpon Biosystems, Inc

Tech Acquisition by Pall

TransCode Therapeutics

IPO, $7M

ViaCell, Inc

IPO and Acquired by Perkin Elmer

Vivo Path LLC

Acquired by Charles River Laboratories

Woodland Biosciences

Acquired by Ichor Life Sciences

Yurogen Biosystems, LLC

Acquired by ABClonal Science Inc.